|

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

RECRUITINGSponsored by Stanford University
Actively Recruiting
SponsorStanford University
Started2004-11
Est. completion2025-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT00373347

Summary

The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
* Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
* Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.

Exclusion Criteria:

-Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.

Conditions3

CancerLiver CancerLiver Disease

Locations1 site

Stanford University School of Medicine
Stanford, California, 94305
Mei-Sze Chua650-724-3525mchua@stanford.edu

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.